Beyond CRISPR? TIGRa: The Tiny Genetic Switch That Could Let the Body Heal Itself

Scientists at Stanford Medicine have built a new tool called TIGRa that can switch on helpful genes directly inside living cells. In a mouse study, it helped protect the eyes from a type of damage seen in glaucoma, and the discovery was published in the journal Cell Stem Cell. It could eventually lead to treatments for many diseases, not just in the eye but potentially in the heart, liver, skin, and brain as well.

You’ve probably heard of CRISPR, the famous gene-editing technology. Beyond cutting DNA, scientists have also adapted CRISPR to simply turn genes up or down without cutting anything, more like a dimmer switch than an on-off switch. This is called gene activation, and it holds huge promise because doctors could boost genes that protect cells or quiet down genes that cause disease. The problem is that these CRISPR-based tools are big and bulky. To get them into the body, doctors usually pack the DNA instructions for building them into a virus, which then delivers those instructions into cells. CRISPR’s instructions are so long that they barely fit inside these tiny viral delivery vehicles, and the problem gets worse if you want to control several genes at once, which many diseases would require.

Researchers went looking for something smaller and found their answer in a recently discovered natural system called TIGR-Tas, first identified in 2025 by scientists studying microbes. Like CRISPR, TIGR-Tas comes from tiny organisms and uses a short piece of guide RNA to find a matching stretch of DNA, but it evolved in a completely different group of organisms and is naturally much more compact. Using this system as a starting point, researchers engineered TIGRa, a gene activator less than half the size of comparable CRISPR-based tools. That smaller size means it fits comfortably inside a single viral vector, along with instructions for switching on several genes at once, something that used to require multiple separate viruses.

Surprisingly, being smaller didn’t make TIGRa weaker. In lab tests, it matched or beat CRISPR activators at turning on genes, and it could activate up to 12 different genes at the same time. As a demonstration of its power, researchers used TIGRa to reprogram ordinary skin cells into stem cells, a process that normally requires switching on seven genes simultaneously.

To see if TIGRa could work as a real therapy, researchers turned to the eye, a favorite testing ground because vision changes are easy to measure, unlike effects inside hidden organs such as the liver. They packaged TIGRa into a virus designed to switch on two protective genes in the nerve cells of the eye that are known to weaken in glaucoma and similar conditions, then delivered it in an animal model before triggering an injury meant to mimic that kind of vision loss. The animals that had received the treatment held on to a meaningful portion of their sight, while those that hadn’t lost most of it, and the protective effect was still holding up months later.

The people behind the work are careful to point out that this is still an early proof of concept rather than a ready-made cure. Still, there’s real optimism about where this could lead. Because TIGRa is so small and flexible, it could eventually be adapted for many different diseases, including heart conditions, liver disease, skin disorders, cancer, neurodegeneration, and stroke.

Source.